Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia LoRusso

Showing results (21-30 of 164) with videos related to

Pageof 17
Sort By:
Journal of Neuro-Oncology|June 5, 2010
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case reportLisa R Rogers, Patricia LoRusso, Paul Nadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2013
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugsDenis L Jardim, Kenneth R Hess, Patricia Lorusso, et al.
Scientific Reports|August 4, 2019
Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass SpectrometryXun Bao, Jianmei Wu, Brian Shuch, et al.
Investigational New Drugs|May 10, 2006
A phase I study of flavopiridol and docetaxelBasil F El-Rayes, Shirish Gadgeel, Ralph Parchment, et al.
Clinical Lung Cancer|July 6, 2011
Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trialsShirish M Gadgeel, Percy Ivy, Wei Chen, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 3, 2024
Unlocking the Potential: Biomarkers of Response to Antibody-Drug ConjugatesLiliana Ascione, Lorenzo Guidi, Ajay Prakash, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2013
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumorsYi-Lin Chiu, Patricia Lorusso, Balakrishna Hosmane, et al.
Journal of the National Cancer Institute|November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trialsSachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Phase I study of bryostatin 1 and gemcitabineBasil F El-Rayes, Shirish Gadgeel, Anthony F Shields, et al.
American Journal of Clinical Oncology|April 7, 2007
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorinBasil F El-Rayes, Mark Zalupski, Anthony F Shields, et al.
Pageof 17

Showing results (21-30 of 164) with videos related to

Sort By:
Pageof 17
Journal of Neuro-Oncology|June 5, 2010
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case reportLisa R Rogers, Patricia LoRusso, Paul Nadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2013
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugsDenis L Jardim, Kenneth R Hess, Patricia Lorusso, et al.
Scientific Reports|August 4, 2019
Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass SpectrometryXun Bao, Jianmei Wu, Brian Shuch, et al.
Investigational New Drugs|May 10, 2006
A phase I study of flavopiridol and docetaxelBasil F El-Rayes, Shirish Gadgeel, Ralph Parchment, et al.
Clinical Lung Cancer|July 6, 2011
Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trialsShirish M Gadgeel, Percy Ivy, Wei Chen, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 3, 2024
Unlocking the Potential: Biomarkers of Response to Antibody-Drug ConjugatesLiliana Ascione, Lorenzo Guidi, Ajay Prakash, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2013
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumorsYi-Lin Chiu, Patricia Lorusso, Balakrishna Hosmane, et al.
Journal of the National Cancer Institute|November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trialsSachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Phase I study of bryostatin 1 and gemcitabineBasil F El-Rayes, Shirish Gadgeel, Anthony F Shields, et al.
American Journal of Clinical Oncology|April 7, 2007
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorinBasil F El-Rayes, Mark Zalupski, Anthony F Shields, et al.
Pageof 17